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Cyclooxygenase-2 (COX-2) expression is mediated by
constitutive NF-B and regulates human gastric cancer
cell growth and proliferation. Inactivating Ku70 or Ku80
suppresses cell growth and induces apoptosis. It has
been hypothesized that Ku70 and Ku80 expression may
be associated with NF-B activation and COX-2 expres-
sion and is involved in cell proliferation. In this study,
we found that inhibition of constitutive NF-B (by trans-
fecting a mutated IB gene) and of COX-2 (by treatment
with indomethacin and NS-398) suppressed Ku70 and
Ku80 expression in cells. Treatment with prostaglandin
E2 adenocarcinoma gastric (AGS) increased expression
of these Ku proteins in cells with low constitutive NF-B
levels. Inhibition of the Ku DNA end-binding activity by
transfection with the C-terminal Ku80 expression gene
suppressed cell proliferation. Ku70 or Ku80 overexpres-
sion by transfection with the Ku70 or Ku80 expression
gene, respectively, enhanced proliferation of cells with
low NF-B levels. These results demonstrate that Ku70
and Ku80 expression is mediated by constitutively acti-
vated NF-B and constitutively expressed COX-2 in gas-
tric cancer cells and that the high Ku DNA end-binding
activity contributes to cell proliferation. Ku70 and Ku80
expression may be related to gastric cell proliferation
and carcinogenesis.
NF-B is an inducible transcription factor that regulates the
activation of a wide variety of genes that respond to immune or
inflammatory signals (1). In resting cells, NF-B is localized to
the cytoplasm as a hetero- or homodimer, which is nonco-
valently associated with the cytoplasmic inhibitory protein
IB. Upon stimulation with a variety of pathogenic inducers
such as viruses, mitogens, bacteria, agents providing oxygen
radicals, and inflammatory cytokines, IB is phosphorylated,
ubiquitinated, and degraded in the cytoplasm, and the NF-B
complex migrates into the nucleus and binds the DNA recog-
nition sites in the regulatory regions of the target genes (2).
However, constitutive NF-B is aberrantly activated in lym-
phomas and human breast and gastric cancer cells in the
resting state (3–6). There are several reports on the role of
NF-B gene products in cell proliferation, transformation, and
tumor development (7, 8). Cyclooxygenase-2 (COX-2),1 an in-
ducible isoform of cyclooxygenase, is also constitutively ex-
pressed in certain groups of cancers (9–11) and is related to cell
proliferation (12, 13). COX-2 inhibition by specific COX-2 in-
hibitors suppresses cell proliferation, induces apoptosis, and
down-regulates the expression of the anti-apoptotic protein
Bcl-2 in pancreatic and colorectal cancer cells (14–19). Pros-
taglandins that are produced via COX-2 include prostaglandin
E2 (PGE2) (20, 21) and prostaglandins A1, A2, and D2 (22). They
are believed to be the major contributors to cell proliferation
and the inflammatory process (23, 24). A previous study dem-
onstrated that COX-2 and prostaglandin syntheses are regu-
lated by constitutive NF-B, which is related to gastric cancer
AGS cell proliferation (11).
The DNA repair protein Ku acts as a heterodimer of the two
70-kDa (Ku70) and 80-kDa (Ku80) subunits and binds to DNA
ends, nicks, or single- to double-strand transition (25, 26). It
serves as a DNA-binding component of a DNA-dependent pro-
tein kinase (DNA-PK) that phosphorylates certain chromatin-
bound proteins in vitro (27, 28). Both Ku and the catalytic
subunit of DNA-PK have been shown to be crucial for DNA
double-strand break repair and V(D)J recombination (29–31).
The Ku heterodimer binds to the double-strand DNA break and
appears to stabilize the binding of the DNA-PK catalytic sub-
unit to the DNA (32–35). Once bound, this complex stimulates
DNA repair and signals the damage/stress responses, which
might affect apoptosis and cell proliferation (36, 37). In addi-
tion, Um et al. (38) showed that Ku activity positively corre-
lates with NF-B activity in multidrug-resistant leukemia
cells. Therefore, Ku activity can be regulated by NF-B activity
and affect cell growth and proliferation. Recent studies re-
vealed growth retardation in both Ku70 and Ku80 knockout
mice. Nussenzweig et al. (39, 40) demonstrated that the
Ku80/ embryonic stem cell line and Ku80/ mutant pri-
mary embryonic fibroblasts display a reduction in cell growth
and induction of cell apoptosis compared with Ku80/ and
Ku80/ control cells. Sadji et al. (41) and Li et al. (42) showed
that human Ku80 knockout colon cells exhibit slower growth
than the corresponding control cells. The growth rate of murine
embryonic fibroblasts derived from Ku70/ embryos is lower
than that of control murine embryonic fibroblasts (43). These
studies show that inactivation of Ku70 or Ku80 drastically
reduces the expression of other Ku subunits, resulting in inac-
tivation of Ku DNA end-binding and DNA-PK activities. More-
over, the loss of one subunit destabilizes the other. Therefore,
growth inhibition of Ku70- or Ku80-deficient cells would result* This study was supported by a grant from the Korean Ministry of
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from inactivation of Ku70 or Ku80 and inhibition of Ku DNA
end-binding and DNA-PK activities. However, the phenotype of
Ku70 knockout mice is somewhat different from that of Ku80
knockout mice (41, 43, 44). These studies suggest that either
Ku70 or Ku80 might have a unique function that is independ-
ent of the other Ku subunit.
As described above, the expression of the COX-2 and Ku
proteins (Ku70 and Ku80) is related to cell proliferation. There-
fore, COX-2 expression mediated by constitutive NF-B might
be associated with the expression of both Ku70 and Ku80. This
aim of this study was to investigate the role of Ku70 and Ku80
in cell proliferation, which may be mediated by constitutively
activated NF-B and constitutively expressed COX-2 in gastric
cancer cells. This study examined whether or not constitutive
NF-B would be inhibited by transfection of the mutated IB
gene and whether constitutively expressed COX-2 inhibited by
treatment with the COX-2 inhibitors indomethacin and NS-398
would suppress Ku70 and Ku80 expression in gastric cancer
AGS cells. To clarify the roles of the Ku DNA end-binding
activity and Ku70 and Ku80 in cell proliferation, either AGS
cells were transfected with the Ku dominant-negative gene to
inactivate the Ku DNA end-binding activity, or the cells were
transfected with either the Ku70 or Ku80 expression gene to
overexpress Ku70 and Ku80, respectively. Cell proliferation
was determined in the transfected cells. In addition, cells with
low constitutive NF-B levels were treated with PGE2 (a
COX-2 product), and the expression of Ku70 and Ku80 in the
cells was determined. A low constitutive NF-B level was con-
firmed by Western blotting for NF-B p65 in cytoplasmic ex-
tracts and nuclear extracts of the cells.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture Conditions—Human gastric cancer AGS cells
(gastric adenocarcinoma, ATCC CRL1739) were obtained from Ameri-
can Type Culture Collection (Manassas, VA) and cultured in RPMI 1640
medium (Sigma) supplemented with 10% fetal bovine serum (Invitro-
gen) and antibiotics (100 units/ml penicillin and 100 g/ml streptomy-
cin). As described previously (11), IW-6 and IW-10 cells and pcN-3 cells
were derived from the AGS cell line stably transfected with the IB
expression vector mutated at serines 32 and 36 (mutated IB gene) to
inhibit NF-B activation and from AGS cells transfected with the con-
trol pcDNA3 vector (Invitrogen), respectively. The IW-6, IW-10, and
pcN-3 cells were cultured and maintained in medium containing 200
g/ml G418 (Invitrogen).
Preparation of Extracts—The cells, which were stably transfected
with the control pcDNA3 vector or the mutated IB gene, were har-
vested with trypsin, washed with ice-cold phosphate-buffered saline,
and lysed by adding SDS buffer (125 mM Tris-HCl (pH 7.5), 5 mM EDTA,
and 1% SDS). The lysates were then boiled for 5 min and centrifuged at
15,000  g for 20 min. The supernatants were collected and used as a
whole cell extract. To prepare the cytoplasmic and nuclear extracts, the
cells were harvested with trypsin, resuspended in 100 l of hypotonic
buffer (10 mM Hepes (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 0.5% Nonidet
P-40, 0.5 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride),
and placed on ice for 20 min. The extracts were centrifuged at 15,000 
g for 20 min at 4 °C. The supernatants were then collected as the
cytoplasmic extracts. The pellets were washed once with hypotonic
buffer, resuspended in 50 l of extraction buffer (20 mM Hepes (pH 7.9),
420 mM NaCl, 0.5 mM EDTA, 1.5 mM MgCl2, 25% glycerol, 0.5 mM
dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride), and placed
on ice for 20 min. The extracts were subsequently centrifuged at
15,000  g for 20 min at 4 °C, and the supernatants were used as the
nuclear extracts. The protein concentration was determined using the
method reported by Bradford (45). For one set of experiments, the cells
were treated with various concentrations of the COX-2 inhibitors indo-
methacin (20, 100, and 200 M; Sigma) and NS-398 (5, 25, and 50 M;
Alexis Biochemicals, San Diego, CA) or PGE2 (14, 140, and 1400 nM;
Sigma) and cultured for 48 h. Indomethacin was dissolved in ethanol,
whereas NS-398 and PGE2 were dissolved in dimethyl sulfoxide. The
final concentration of each vehicle was 0.1%. The vehicle-treated cells
were used as the control. The drug concentrations used in this study
were adapted from a previous study (11). The whole cell, cytoplasmic,
and nuclear extracts from the cells treated with either the COX-2
inhibitors or PGE2 were prepared as described above.
Western Blot Analysis—Whole cell extracts (40 g of protein/lane),
cytoplasmic extracts (60 g of protein/lane), or nuclear extracts (10 g
of protein/lane) were loaded, separated by 8% SDS-PAGE under reduc-
ing conditions, and transferred onto nitrocellulose membranes (Amer-
sham Biosciences) by electroblotting. Protein transfer and equality of
loading in the lanes were verified using reversible staining with Pon-
ceau S. The membranes were blocked with 5% nonfat dry milk in
Tris-buffered saline and 0.15% Tween 20 (TBS-T) for 3 h at room
temperature. The proteins were detected with polyclonal antibodies
against Ku70 (1:1000; sc-1487), Ku80 (1:500; sc-1484), actin (1:1000;
sc-1615), NF-B p65 (1:1000; sc-372), aldolase A (1:500; sc-12059), and
histone H1 (1:500; sc-8615) (all from Santa Cruz Biotechnology, Santa
Cruz, CA) diluted in TBS-T containing 5% dry milk and incubated at
4 °C overnight. After washing with TBS-T, the immunoreactive pro-
teins were visualized using horseradish peroxidase-conjugated goat
anti-rabbit secondary antibodies, followed by enhanced chemilumines-
cence (Amersham Biosciences). Actin was used for the protein loading
control, whereas aldolase A and histone H1 were used for the cytoplas-
mic and nuclear controls, respectively.
Reverse Transcription (RT)-PCR Analysis—Ku70 and Ku80 mRNA
expression was assessed by RT-PCR analysis, followed by Southern
hybridization, and quantitated using the -actin housekeeping gene as
the internal control. Briefly, the total RNA was extracted, reverse-
transcribed into cDNA, and used for PCR with specific human primers
for Ku70, Ku80, and -actin. The sequences of the Ku70 primers were
5-ATGGCAACTCCAGAGCAGGTG-3 (forward primer) and 5-AGT-
GCTTGGTGAGGGCTTCCA-3 (reverse primer), giving a 462-bp PCR
product (46). For the Ku80 primers, the forward primer was 5-TGACT-
TCCTGGATGCACTAATCGT-3, and the reverse primer was 5-TTG-
GAGCCAATGGTCAGTCG-3, giving a 454-bp PCR product (47). The
-actin primers used were 5-ACCAACTGGGACGACATGGAG-3 (for-
ward primer) and 5-GTGAGGATCTTCATGAG GTAGTC-3 (reverse
primer), giving a 349-bp PCR product (48). Briefly, the PCR products
were amplified by 18–19 repeated denaturation cycles at 95 °C for 30 s,
annealing at 60 °C for 30 s, and extension at 72 °C for 30 s. The 95 °C
step was extended to 2 min during the first cycle, and the 72 °C step was
extended to 5 min during the final cycle. The PCR products were
separated on 1.5% agarose gels containing 0.5 g/ml ethidium bromide
and transferred to a Hybond-N nylon membrane, and the membrane
was hybridized overnight at 60 °C with the respective digoxigenin-
labeled probe (49). After 20-min washes with 2 and 0.2 SSC buffer
containing 0.1% SDS at room temperature and at 60 °C, the digoxigenin
label was immunodetected using the digoxigenin detection kit (Roche
Molecular Biochemicals, Mannheim, Germany) according to the manu-
facturer’s protocol. Hybridized bands for PCR products were quantified
by densitometric analysis. The Ku70 and Ku80 mRNA levels were
quantitated using -actin. The Ku70 and Ku80 mRNA levels in pcN-3
cells were considered as 100%. Each bar in the figures represents the
mean  S.E. of three separate experiments. The reverse transcriptase
negative control was treated without reverse transcriptase, but follow-
ing the same procedure as used for the other samples.
Plasmid Construction—The human cDNAs for Ku70 and Ku80 were
derived from human pET1a-Ku70 and pET1a-Ku80 (a kind gift from T.
Morio, Tokyo Medical and Dental University), respectively. The insert
was digested with BamHI and EcoRI and subcloned into the BamHI-
EcoRI sites of the pcDNA3 vector. A C-terminal human Ku80-(427–732)
expression vector was generated by PCR using a Ku80 cDNA vector
with a specific set of primers to generate artificial KpnI and BamHI
sites at the 5- and 3-ends, respectively. The sequences of the primers
used are as follows: 5-TGCAGGTACCTATCATGGAAGACTTGCG-3
and 5-GGT ACC TAG GTG CTG GAT ATA GTA CAG G-3. A KpnI-
BamHI fragment of the product was subcloned into the KpnI and
BamHI sites of the pcDNA3 vector. The PCR-derived part was con-
firmed by sequencing analysis.
Transfection—Subconfluent AGS cells were plated in 10-cm culture
dishes and transfected with 10 g of the C-terminal Ku80-(427–732)
expression plasmid construct using DOTAP (Roche Molecular Bio-
chemicals) for 16 h. After transfection, the cells were trypsinized and
plated at 1  104 cells/10-cm culture dish. The cells were cultured in
medium containing 400 g/ml G418 for 15–17 days, and three to four
resistant clones were isolated from each plate. The Ku DNA end-
binding activity was determined by an electrophoretic mobility shift
assay (EMSA). The positive clones for C-terminal Ku80-(427–732) were
maintained in culture medium containing 200 g/ml G418 for 2
months and are referred to as KuDN-2 and KuDN-7. For the transient
transfection of Ku70 or Ku80 into AGS cells, the cells, which were
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previously stably transfected with either the mutated IB gene or the
control pcDNA3 vector, were plated in a 10-cm culture dish and cul-
tured overnight. The cells were transfected with either the Ku70 or
Ku80 expression plasmid construct using DOTAP for 16 h. The cells
were replated in a 10-cm culture dish and cultured for a further 48 h.
Nuclear and cytoplasmic extracts were prepared from the cells. The
Ku70 and Ku80 protein levels were determined by Western blot
analysis.
EMSA—EMSA was carried out by a slight modification of the
method reported by Kim et al. (50). Nuclear extracts (10 g) of the cells
transfected with the C-terminal Ku80-(427–732) expression gene were
incubated with the 32P-labeled double-stranded oligonucleotide 5-
GGGCCAAGAATCTTAGCAGTTTCGGG-3 in buffer containing 12%
glycerol, 12 mM Hepes (pH 7.9), 1 mM EDTA, 1 mM dithiothreitol, 25 mM
KCl, 5 mM MgCl2, and 0.04 g/ml poly[d(I-C)] at room temperature for
30 min. The extracts were then subjected to electrophoretic separation
at room temperature on a nondenaturing 5% acrylamide gel at 30 mA
using 0.5 Tris borate/EDTA buffer. The gels were dried at 80 °C for 1 h
and exposed to radiography film for 6–18 h at 70 °C with intensifying
screens (51). For the supershift assay, 10 g of nuclear extracts were
preincubated with 1 g of polyclonal antibody specific to Ku70 or Ku80
on ice for 30 min prior to the Ku DNA end-binding reaction.
Cell Counting and MTT Assay—Cell number was determined by both
direct counting with a hemocytometer using the trypan blue exclusion
test (0.2% trypan blue) and an indirect colorimetric immunoassay (MTT
assay). MTT was metabolized by NAD-dependent dehydrogenase to
form a colored reaction product, and the amount of dye formed directly
correlated with the number of cells. For the trypan blue exclusion test,
the cells were plated at 2  104 cells/well in a 24-well culture plate and
incubated for 24, 48, and 72 h. The number of cells was counted with a
hemocytometer using 0.2% trypan blue. For the MTT assay, the cells
(2  103 cells/well) were plated in a 96-well culture plate and cultured
for 48 h. MTT (0.5 mg/ml) was added, and the reaction mixture was
incubated for 4 h at 37 °C. The cellular formazan was extracted with
acidic propan-2-ol, and the absorbance was measured with a dual-
wavelength automatic plate reader at 570/630 nm (52). The number of
viable cells is expressed as MTT-positive cells, and the number of cells
transfected with the control pcDNA3 vector (pcN-3 in Fig. 5 and pcDNA
in Fig. 8) was considered to 100%. The relative numbers of MTT-
positive cells are expressed as a percentage of the pcN-3 (see Fig. 5) or
pcDNA3-transfected (see Fig. 8) cells.
Determination of [3H]Thymidine Incorporation—The cells (5  104/
well) were seeded in a 24-well culture plate. After incubating the cells
for 24 h, 1 Ci/ml [3H]thymidine (Amersham Biosciences) was added,
and incubation was continued for an additional 6 h. The cells were then
washed twice with ice-cold phosphate-buffered saline, incubated in 10%
trichloroacetic acid for 30 min, and incubated with a solution consisting
of 0.3 M NaOH and 1% SDS for 1 h. The cells were lysed by vortexing
and analyzed for their radioactivity by liquid scintillation counting.
[3H]Thymidine incorporation, which reflected the extent of DNA syn-
thesis, in the cells transfected with the control pcDNA3 vector (pcN-3 in
Fig. 5 and pcDNA in Fig. 8) was considered as 100%. The relative
amount of [3H]thymidine incorporated is expressed as a percentage of
the pcN-3 (see Fig. 5) or pcDNA3-transfected (see Fig. 8) cells.
Statistical Analysis—The results are expressed as means  S.E. of
four separate experiments. Analysis of variance followed by Newman-
Keuls test was used for statistical analysis (53). p 0.05 was considered
statistically significant.
RESULTS
Decreased Expression of Ku70 and Ku80 in AGS Cells Trans-
fected with the Mutated IB Gene—A previous study demon-
strated that AGS cells stably transfected with the mutated
IB gene (IW-6 and IW-10) have lower constitutive NF-B
levels and slower cell proliferation compared with AGS cells
transfected with the control pcDNA3 vector (pcN-3) (11). The
Ku70 or Ku80 antigen is related to cell growth and prolifera-
tion (39–43). It was hypothesized that constitutive NF-B ac-
tivation might be associated with Ku80 and Ku70 expression.
To confirm this hypothesis, the Ku70 and Ku80 protein and
mRNA levels in AGS cells, which were previously transfected
with the mutated IB gene or the control pcDNA3 vector,
were analyzed by Western blot analysis and RT-PCR analysis,
respectively (Fig. 1). The Ku70 and Ku80 protein levels in the
IW-6 and IW-10 cells were lower than those in the pcN-3 cells
(Fig. 1A). The Ku70 and Ku80 mRNA levels in the IW-6 and
IW-10 cells were lower than those in both the wild-type and
pcN-3 cells. The Ku70, Ku80, and -actin mRNA levels were
not detected in the reverse transcriptase negative control,
which was treated without reverse transcriptase in the PCR
procedure (Fig. 1B). Furthermore, to investigate the expression
and intracellular localization of Ku70 and Ku80 in cells trans-
fected with the mutated IB gene or the control pcDNA3
vector, the Ku protein levels were analyzed in both the nuclear
and cytoplasmic extracts by Western blot analysis. A low nu-
clear level of NF-B p65 was determined in IW-6 and IW-10
cells. The nuclear levels of Ku70 and Ku80 were lower in the
IW-6 and IW-10 cells than in the wild-type and pcN-3 cells.
Aldolase was detected only in the cytoplasmic extracts,
whereas histone H1 was observed only in the nuclear extracts
(Fig. 1C). This suggests that the inhibition of constitutive
NF-B activation, which was associated with the suppression
of cell growth and proliferation in a previous study (11), may be
caused by a reduction in Ku70 and Ku80 expression. Therefore,
the effects of COX-2 inhibitors suppressing cell proliferation on
Ku70 and Ku80 expression were determined because the con-
FIG. 1. The Ku70 and Ku80 protein and mRNA levels in AGS
cells transfected with either the control vector or the mutated
IB gene. A, the whole cell extracts were prepared from wild-type
cells, and the cells were transfected with the control pcDNA3 vector
(pcN-3) or the mutated IB gene (IW-6 and IW-10). The Ku70 and
Ku80 protein levels were determined by Western blot analysis. Actin
was used for the loading control. B, the total RNAs were extracted from
the cells. The Ku70 and Ku80 mRNA levels were determined by RT-
PCR analysis, followed by Southern hybridization (upper panel), and
quantitated using the -actin housekeeping gene (lower panel). The
Ku70 and Ku80 mRNA levels of pcN-3 cells were considered as 100%.
Each bar represents the mean  S.E. of three separate experiments.
The reverse transcriptase negative control (RT()) was treated without
reverse transcriptase and was subjected to the same procedure as the
other samples. C, cytoplasmic and nuclear extracts were prepared from
the cells. The Ku70 and Ku80 protein levels as well as the NF-B p65
protein level were determined by Western blot analysis. Aldolase and
histone H1 were used as the cytoplasmic and nuclear controls,
respectively.
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stitutive expression of COX-2 is mediated by constitutive
NF-B in AGS cells.
Effects of COX-2 Inhibitors on the Expression of Ku70 and
Ku80—Several reports have shown that constitutive COX-2 is
related to the proliferation of certain cancer cells (14–18). It
was previously demonstrated that inhibiting COX-2 expression
by specific COX-2 inhibitors suppresses AGS cell growth and
proliferation (11). Therefore, COX-2 inhibition was examined
to determine whether it could reduce the Ku70 and Ku80
expression levels. Treatment with a nonspecific COX-2 inhibi-
tor (indomethacin) resulted in a dose-dependent suppression of
the Ku70 and Ku80 protein and mRNA levels after 48 h of
treatment (Fig. 2, A and B). Similar results were observed after
treatment with a specific COX-2 inhibitor (NS-398). The inhib-
itory effect of NS-398 on Ku70 and Ku80 expression was more
potent than that of indomethacin. The Ku70 and Ku80 protein
levels in the nuclear extracts were significantly lower in the
cells treated with indomethacin (200 M) and NS-398 (50 M)
than in the control cells treated with each vehicle (Fig. 2C).
These results demonstrate that COX-2 expression is positively
related to Ku70 and Ku80 expression in gastric cancer AGS
cells.
Effects of PGE2 on the Expression of Ku70 and Ku80—Pros-
taglandins that are produced by COX-2 have diverse bioactive
activities, including growth-promoting actions in colon and gas-
tric cancer cells (23–24). PGE2 was investigated to determine
whether it could enhance Ku70 and Ku80 expression. The
effects of PGE2 on the Ku70 and Ku80 protein and mRNA
levels were determined in AGS cells transfected with either the
mutated IB gene or the control pcDNA3 vector after 48 h of
treatment (Fig. 3, A and B). Treatment with PGE2 dose-de-
pendently increased the Ku70 and Ku80 protein and mRNA
levels in the IW-10 cells. PGE2 did not affect the Ku70 and
Ku80 protein and mRNA levels in the pcN-3 cells. These results
suggest that Ku70 and Ku80 expression is not induced in cells
FIG. 2. Effects of COX-2 inhibitors on the Ku70 and Ku80 pro-
tein and mRNA levels in AGS cells. The cells (plated at 1.5  106
cells/dish) were treated with various concentrations of indomethacin or
NS-398 for 48 h. A, the whole cell extracts were prepared from the cells,
and Ku70 and Ku80 protein levels were determined by Western blot
analysis. Actin was used for the loading control. B, the total RNAs were
extracted from the cells. The Ku70 and Ku80 mRNA levels were deter-
mined by RT-PCR analysis, followed by Southern hybridization (upper
panel), and quantitated using the -actin housekeeping gene (lower
panel). The Ku70 and Ku80 mRNA levels of pcN-3 cells were considered
as 100%. Each bar represents the mean  S.E. of three separate
experiments. The reverse transcriptase negative control (RT()) was
treated without reverse transcriptase and was subjected to the same
procedure as the other samples. C, the cytoplasmic and nuclear extracts
were prepared from the cells treated with vehicle (ethanol for indo-
methacin and dimethyl sulfoxide) for NS-398 (Control), 200 M indo-
methacin, or 50 M NS-398 for 48 h. The Ku70 and Ku80 protein levels
were determined by Western blot analysis. Aldolase and histone H1
were used as the cytoplasmic and nuclear controls, respectively.
FIG. 3. Effects of PGE2 on the Ku70 and Ku80 protein and
mRNA levels in AGS cells transfected with the control vector or
the mutated IB gene. pcN-3 and IW-10 cells were plated at of 1.5
106 cells/dish. The cells were treated with various concentrations of
PGE2 for 48 h. A, the whole cell extracts were prepared from the cells,
and the Ku70 and Ku80 protein levels were determined by Western blot
analysis. Actin was used for the loading control. B, the total RNAs were
extracted from the cells. The Ku70 and Ku80 mRNA levels were deter-
mined by RT-PCR analysis, followed by Southern hybridization (upper
panel), and quantitated using the -actin housekeeping gene (lower
panel). The Ku70 and Ku80 mRNA levels in pcN-3 cells were considered
as 100%. Each bar represents the mean  S.E. of three separate
experiments. The reverse transcriptase negative control (RT()) was
treated without reverse transcriptase and subjected to the same proce-
dure as the other samples. C, the cytoplasmic and nuclear extracts were
prepared from cells treated with the vehicle dimethyl sulfoxide (Con-
trol) or 1400 nM PGE2 for 48 h. The Ku70 and Ku80 protein levels were
determined by Western blot analysis. Aldolase and histone H1 were
used as the cytoplasmic and nuclear controls, respectively.
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where COX-2 is highly constitutively expressed. Treatment
with PGE2 (1400 nM) prevented the decrease in the Ku70 and
Ku80 protein levels in the IW-10 cells (Fig. 3C). This shows
that prostaglandins produced by COX-2 might induce Ku70
and Ku80 expression in cells with a low COX-2 expression
level.
Proliferation of AGS Cells Transfected with the C-terminal
Ku80-(427–732) Expression Gene—To inhibit the Ku DNA end-
binding activity, AGS cells were transfected with the vector
containing the terminal 926 bp of the Ku80 cDNA, correspond-
ing to the C-terminal 305 amino acids of the Ku80 protein,
referred to the C-terminal Ku80-(427–732) expression gene.
This fragment could interact with Ku70, but the heterodimer of
Ku70 and C-terminal Ku80 could not bind to the double-
stranded DNA ends, resulting in decreased Ku-dependent DNA
end-binding activity in the cells (54–57). In this study, AGS
cells were stably transfected with the C-terminal Ku80-(427–
732) expression gene. The stably transfected clones of the C-
terminal Ku80-(427–732) expression gene (KuDN-2 and
KuDN-7) were then selected and analyzed for Ku DNA end-
binding activity by EMSA (Fig. 4). A single slowly migrating
band appeared in the gel that was supershifted in the presence
of anti-Ku70 and anti-Ku80 antibodies. This retarded band can
be confidently ascribed to a KuDNA complex. The intensity of
this band was lower in the cells transfected with the C-terminal
Ku80-(427–732) expression gene (KuDN-2 and KuDN-7) than
in both the wild-type and pcN-3 cells. Because there was no
evidence of smaller DNA end-binding product(s) in the cells
transfected with the C-terminal Ku80-(427–732) expression
gene, neither C-terminal Ku80-(427–732) alone nor a putative
heterodimer of Ku70 and C-terminal Ku80-(427–732) exhibited
DNA end-binding activity. To evaluate the relationship be-
tween inhibition of the Ku DNA end-binding activity and cell
proliferation, the cells were transfected with either the C-
terminal Ku80-(427–732) expression gene (KuDN-2 and
KuDN-7) or with the control pcDNA3 vector (pcN-3) and cul-
tured. The number of viable cells was determined by the trypan
blue exclusion test (Fig. 5A). Cell proliferation was lower in the
cells transfected with the C-terminal Ku80-(427–732) expres-
sion gene (KuDN-2 and KuDN-7) than in the wild-type cells
and the cells transfected with the control pcDNA3 vector
(pcN-3) for a 72-h culture period. A similar phenomenon was
shown by other methods determining the MTT-positive cells
(Fig. 5B) and [3H]thymidine incorporation (Fig. 5C). The num-
ber of MTT-positive cells and the extent of [3H]thymidine in-
corporation were lower in the cells transfected with the C-
terminal Ku80-(427–732) expression gene than in the wild-type
and pcN-3 cells. This shows that the inhibition of the Ku DNA
end-binding activity results in a strong down-regulation of cell
proliferation.
Proliferation of AGS Cells Transfected with the Ku70 or Ku80
Expression Gene—pcN-3 and IW-10 cells were transiently
transfected with the cDNA for p70 (Ku70) or p80 (Ku80). The
Ku70 and Ku80 protein expression levels in these cells were
determined by Western blot analysis (Fig. 6). The nuclear level
of Ku70 in the IW-10 cells transfected with the cDNA for Ku70
(pcDNA-Ku70) was significantly higher than in the wild-type
IW-10 cells and in the IW-10 cells transfected with the control
vector (pcDNA). Correspondingly, the nuclear level of Ku80 in
the IW-10 cells transfected with the cDNA for Ku80
(pcDNA-Ku80) was significantly higher than in the wild-type
IW-10 cells and the IW-10 cells transfected with the control
pcDNA3 vector (Fig. 6B). These effects were similar to those
shown in pcN-3 cells (Fig. 6A). However, increases in the nu-
clear levels of both Ku70 by the transfection of the Ku70 ex-
FIG. 4. Ku DNA end-binding activity in a nuclear extract of
AGS cells transfected with the C-terminal Ku80-(427–732) ex-
pression gene. The nuclear extracts (10 g) were prepared from wild-
type cells, pcN-3 cells, and cells transfected with the C-terminal Ku80-
(427–732) expression gene (KuDN-2 and KuDN-7). The Ku DNA end-
binding activity was determined by EMSA. For the supershift assay,
the nuclear extracts were preincubated with anti-Ku70 or anti-Ku80
antibody and subjected to EMSA. Control represents the Ku DNA
end-binding activity from the nuclear extract preincubated without
antibody.
FIG. 5. Proliferation of AGS cells transfected with the control
vector or with the C-terminal Ku80-(427–732) expression gene as
determined by cell counting, MTT-positive cells, and [3H]thymi-
dine incorporation. A, for viable cell counting, wild-type cells, pcN-3
cells, and cells transfected with the C-terminal Ku80-(427–732) expres-
sion gene (KuDN-2 and KuDN-7) were plated at 2  104 cells/well. The
cells were incubated for the indicated time periods, and cell number was
counted using a trypan blue exclusion test. Each point represents the
mean  S.E. of four separate experiments. *, p  0.01 versus pcN-3 at
each time point. B, for the analysis of MTT-positive cells, cells (2  103
cells/well) were plated and cultured for 48 h. Viable cells were assessed
by the MTT assay, and MTT-positive cells are expressed as a percentage
of the pcN-3 cells. The relative MTT-positive cells are expressed as a
percentage of the pcN-3 cells. Each bar represents the mean  S.E. of
four separate experiments. *, p  0.01 versus pcN-3 cells. C, for the
[3H]thymidine incorporation assay, the cells were plated at 5  104
cells/well and cultured for 24 h. The cells were cultured for 6 h after
adding 1 Ci/ml [3H]thymidine. The amount of [3H]thymidine incorpo-
rated into the pcN-3 cells was considered as 100%. The relative [3H]thy-
midine incorporation is expressed as a percentage of the pcN-3 cells.
Each bar represents the mean  S.E. of four separate experiments.
*, p  0.01 versus pcN-3 cells.
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pression gene and Ku80 by the transfection of the Ku80 expres-
sion gene in the pcN-3 cells were relatively lower than those in
the IW-10 cells. This may have been caused by the relatively
low expression levels of the Ku proteins in the IW-10 cells
compared with those in the pcN-3 cells. The cytoplasmic levels
of Ku70 and Ku80 were unchanged by transfection with the
Ku70 or Ku80 expression gene. In addition, transfection with
the Ku70 expression gene did not affect the nuclear level of
Ku80, and transfection with the Ku80 expression gene had no
effect on the nuclear level of Ku70 in either the pcN-3 or IW-10
cells.
Proliferation of the wild-type pcN-3 cells (Fig. 7A) was higher
than that of the wild-type IW-10 cells (Fig. 7B) containing low
nuclear levels of NF-B and Ku proteins during a 72-h culture
period. To evaluate the relationship between overexpression of
the Ku70 and Ku80 proteins and cell proliferation, the cells
were transfected with the cDNA for either Ku70 or Ku80
(pcDNA-Ku70 and pcDNA-Ku80) or with the control pcDNA3
vector (pcDNA) and cultured. Cell proliferation was deter-
mined by the relative number of MTT-positive cells and the
extent of [3H]thymidine incorporation (Figs. 7 and 8). In the
IW-10 cells, proliferation was significantly higher in the cells
transfected with the cDNA for either Ku70 or Ku80 than in the
wild-type and pcDNA3-transfected cells. The increase in pro-
liferation was slightly higher in the Ku80-overexpressing
IW-10 cells than in the Ku70-overexpressing IW-10 cells. How-
ever, the effect of Ku70 and Ku80 cDNA transfection on the
increase in cell proliferation was lower in the pcN-3 cells. This
demonstrates that Ku70 and Ku80 overexpression induces a
strong up-regulation of cell proliferation, which is correlated
with the nuclear levels of Ku70 and Ku80.
DISCUSSION
NF-B is constitutively activated in B-cell lymphoma, breast,
and gastric cancer cells (3–6, 11). Cell proliferation and tumor-
igenesis involve the constitutive induction of NF-B activation
(58–62). The NF-B target genes have been implicated in the
prevention of cell death by regulating the expression of genes
such as those for the tumor necrosis factor receptor-associated
factors TRAF1 and TRAF2, the inhibitor of apoptosis proteins
c-IAP1 and c-IAP2, Bcl-xL, and Bcl-2 (63, 64). COX-2 is consti-
tutively expressed in some cancers (9–11) and is related to cell
proliferation (12, 13). Sasaki et al. (65) reported that NF-B is
constitutively activated in human gastric carcinoma tissue as
opposed to adjacent normal epithelial cells. Premalignant and
malignant gastric lesions exhibit strong COX-2 expression,
which is not observed in normal lesions (66, 67). A previous
study demonstrated that constitutively expressed COX-2,
which is mediated by constitutive NF-B, regulates gastric
cancer AGS cell proliferation (11). This suggests that constitu-
tive COX-2 expression via constitutive NF-B may be a prin-
cipal mechanism for gastric carcinogenesis and tumorigenesis.
Several studies have shown that inhibiting the expression of
either Ku70 or Ku80 results in inhibition of cell growth and
induction of apoptosis (39–43).
In this study, constitutively activated NF-B and COX-2
expression were examined to determine whether they could
regulate Ku70 or/and Ku80 expression in gastric cancer AGS
cells. AGS cells with a low level of constitutive NF-B had a
lower expression level of Ku70 and Ku80, which was reflected
in the lower nuclear levels of Ku proteins, than the wild-type
cells and the cells transfected with control vector. This finding
contrasts with the report by Um et al. (38), who showed that
PC-12-NF-B cells overexpressing both p50 and p65 subunits
of NF-B exhibited an increase in Ku70 and Ku80 expression
compared with the parental PC-12 cells. COX-2 inhibitors such
as indomethacin and NS-398 were found to suppress Ku70 and
Ku80 expression in AGS cells. PGE2, a COX-2 product, en-
hanced the Ku70 and Ku80 expression levels in the cells with
low constitutive NF-B levels. These results suggest that Ku70
and Ku80 expression may be regulated by COX-2 and COX-2
products (prostaglandins) via an NF-B-dependent mechanism
in AGS cells. Prostaglandins exert their biological action via
specific receptors (prostaglandin E receptors 1–4) (68). Pai et
al. (69) reported that PGE2 transactivates the epidermal
growth factor receptors, which then trigger mitogenic signaling
(70–72). Efficient DNA repair in actively growing cells requires
FIG. 6. Ku70 and Ku80 protein levels in the cytoplasmic and
nuclear extracts of pcN-3 and IW-10 cells transfected with the
Ku70 or Ku80 expression gene. pcN-3 and IW-10 cells were tran-
siently transfected with the Ku70 or Ku80 expression gene
(pcDNA-Ku70 and pcDNA-Ku80, respectively). The cytoplasmic and
nuclear extracts were prepared from pcN-3 (A) and IW-10 (B) cells
transfected with or without the Ku70 or Ku80 expression gene. The
Ku70 and Ku80 protein levels were determined by Western blot anal-
ysis. Wild, non-transfected cells; pcDNA, cells transfected with the
control pcDNA3 vector. Aldolase and histone H1 were used as the
cytoplasmic and nuclear controls, respectively.
FIG. 7. Effect of transfection with the Ku70 or Ku80 expression
gene on the proliferation of pcN-3 and IW-10 cells as determined
by cell counting. pcN-3 (A) and IW-10 (B) cells were transiently
transfected with the control pcDNA3 vector (pcDNA) or with the Ku70
or Ku80 expression gene (pcDNA-Ku70 and pcDNA-Ku80, respectively).
The cells were plated at 2  104 cells/well and then incubated for the
indicated time periods. The number of cells was counted by the trypan
blue exclusion test. Each point represents the mean  S.E. of four
separate experiments. *, p  0.01 versus pcDNA3-transfected cells at
each time point. Wild, non-transfected cells.
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growth factor signaling (73, 74). Epidermal growth factor re-
ceptor-mediated signaling is associated with mitogenesis and
cell proliferation (75, 76). Because epidermal growth factor
receptor signaling requires the maintenance of a nuclear level
of DNA-PK and its regulatory heterodimeric complex
(Ku70Ku80) in mammalian cells (77), the role of Ku70Ku80 in
cell proliferation and growth is postulated. Further study
should be performed to determine whether the prostaglandins
produced by COX-2 activate specific receptors such as epider-
mal growth factor and other growth factor receptors, triggering
specific signaling related to Ku70 and Ku80 expression in gas-
tric cancer cells. In addition, a heterodimer of Ku70 and Ku80
is a regulatory subunit of DNA-PK that phosphorylates many
proteins, including transcription factors such as c-Jun, c-Fos,
c-Myc, and many more. They appear to be multifunctional
proteins that are implicated in cellular processes such as DNA
replication, transcriptional regulation, and control of the G2
and M phases of the cell cycle (78). Therefore, Ku70 and Ku80
may be involved in cell proliferation by regulating cell cycle-
associated proteins or growth-related gene expression.
This study demonstrated that the inhibition of the Ku DNA
end-binding activity by transfection of the C-terminal Ku80-
(427–732) expression gene resulted in the suppression of AGS
cell proliferation. Several reports have shown that inactivating
Ku80 or Ku70 reduces the expression of the other Ku subunit
(Ku70 or Ku80) and then inhibits the Ku DNA end-binding and
DNA-PK activities in Ku70- or Ku80-deficient cells (39–43).
These results suggest that disruption of either of the Ku sub-
units would reduce the Ku DNA end-binding activity, which
then would inhibit the functional role of the Ku proteins.
Therefore, inhibition of the cell growth caused by a reduction in
the Ku70 and Ku80 nuclear levels may be related to the loss of
the Ku DNA end-binding activity. This was proven by the
observation that inhibition of the Ku DNA end-binding activity
by transfection with C-terminal Ku80-(427–732) resulted in
inhibition of cell proliferation. These results show that Ku70 or
Ku80 overexpression in AGS cells with a low constitutive
NF-B level does not induce an increase in the nuclear level of
the other Ku subunit (Ku80 or Ku70), which concurs with a
previous report (79). Overexpression of either Ku70 or Ku80
without enhancement of the other Ku subunit induced an in-
crease in cell proliferation. Null knockout mice for DNA-PKcs
do not exhibit growth retardation, whereas growth retardation
has been observed in either Ku70 or Ku80 knockout mice (40,
43, 44, 80). This suggest that Ku70 and Ku80 are associated
with growth regulation independent of the function of DNA-
PK. Ku70 has been reported to show Ku80-dependent and
Ku80-independent DNA binding (81). In recent studies using
knockout mice, some differences in the phenotypes of Ku70 and
Ku80 knockout mice have been reported (40, 43, 44), suggest-
ing the possibility that Ku70 and Ku80 may have unique func-
tions, including cell proliferation, that are independent of the
other Ku subunit. It has been reported that a Ku70 and Ku80
deficiency (but not a DNA-PKcs deficiency) results in a dra-
matic increase in cell apoptosis (39, 40, 42, 82). However, we
found that inhibiting Ku70 and Ku80 expression by the COX-2
inhibitors and transfection of C-terminal Ku80-(427–732) did
not induce apoptosis, as determined by the DNA fragmentation
assay (data not shown). In addition, Ku70 or/and Ku80 expres-
sion may have anti-apoptotic properties because inhibition of
Ku70 and Ku80 suppressed cell proliferation. These results are
supported by Li et al. (42), who demonstrated that Ku80 inac-
tivation results in induction of the tumor suppressor protein
p53, which contributes to inhibition of cell growth. However, it
was previously determined that the proliferation of AGS cells
with low Ku70 and Ku80 expression levels was not associated
with p53 expression and that inhibition of Ku expression after
treatment with COX-2 inhibitors did not induce p53 expression
(data not shown).
PGE2 (produced by COX-2) decreases cell death and regu-
lates cultured tumor cell proliferation (83). Inhibition of PGE2
production by sulindac (84) has a marked inhibitory effect on
the development of colon tumors in mice (85). In addition, PGE2
induces Bcl-2 expression in human colon cancer cells (14).
COX-2 inhibition by NS-398 induces apoptosis with a lower
Bcl-2 protein level in human prostate cancer cells (18). Gao et
al. (67) reported that Bcl-2 and COX-2 (but not p53) might play
a role in the early genesis/progression of a gastric carcinoma.
Therefore, PGE2 might be involved in cell growth and prolifer-
ation and enhance the tumorigenic potential in some cancer
cells. In B-cell chronic lymphocytic leukemia, the level of anti-
apoptotic Bcl-2 shows a positive correlation with the Ku80 level
(86). Ku70 and Ku80 expression is higher in aggressive breast
tumors compared with normal tissue (87). These studies sug-
FIG. 8. Effect of transfection with the Ku70 or Ku80 expression
gene on the proliferation of pcN-3 and IW-10 cells as determined
by MTT-positive cells and [3H]thymidine incorporation. For
analysis of MTT-positive cells, pcN-3 (A) and IW-10 (B) cells were
transiently transfected with the control pcDNA3 vector (pcDNA) or
with the Ku70 or Ku80 expression gene (pcDNA-Ku70 and
pcDNA-Ku80, respectively). The cells were plated at 2  103 cells/well
and cultured for 48 h. Viable cells were assessed by the MTT assay, and
MTT-positive cells are expressed as a percentage of the cells transfected
with the control pcDNA3 vector. The relative MTT-positive cells are
expressed as a percentage of the pcDNA3-transfected cells. Each bar
represents the mean  S.E. of four separate experiments. *, p  0.05
versus pcN-3 cells; **, p  0.01 versus pcN-3 cells. For determination of
[3H]thymidine incorporation, the pcN-3 (C) and IW-10 (D) cells were
transiently transfected with the control pcDNA3 vector or with the
Ku70 or Ku80 expression gene. The cells were plated at 5  104
cells/well and cultured for 24 h. After adding 1 Ci/ml [3H]thymidine,
the cells were cultured for 6 h. The level of [3H]thymidine incorporation
in the cells transfected with the control pcDNA expression vector was
considered as 100%. The relative [3H]thymidine incorporation level is
expressed as a percentage of the pcDNA3-transfected cells. Each bar
represents the mean  S.E. of four separate experiments. *, p  0.05
versus pcN-3 cells; **, p  0.01 versus pcN-3 cells.
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gest a possible relationship among PGE2 produced by COX-2;
the levels of Bcl-2, Ku70, and Ku80; and cancer cell prolifera-
tion. It is suggested that the gastric cell hyperproliferation
associated with carcinogenesis might be associated with both
high expression and high nuclear levels of Ku70 and Ku80 in a
COX-2-dependent mechanism, which is mediated by NF-B
activation in gastric cancer cells. Further study should focus on
the action mechanism of COX-2 and its products in Ku70 and
Ku80 expression and the possible mechanism and mediator(s)
that induce cell proliferation by Ku70 and Ku80 in gastric
cancer cells.
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